Therapeutic agents for treating restless leg syndrome
The present disclosure provides for treatments of restless legs syndrome (RLS) or one or more symptoms associated with RLS comprising administering leucine, acetyl-leucine or a pharmaceutically acceptable salt thereof.
1. A method of treating restless legs syndrome (RLS) or one or more symptoms associated with RLS in a subject in need thereof comprising:
administering leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof to the subject.
2. The method according to claim 1 , wherein the RLS is primary RLS.
3. The method according to claim 1 , wherein the RLS is secondary RLS.
4. The method according to claim 1 , wherein the method comprises administering to the subject a therapeutically effective amount of the leucine, acetyl-leucine, or pharmaceutically acceptable salt thereof.
5. The method according to claim 4 , wherein the administration occurs over time and the subject's International Restless Leg Syndrome Rating Scale (IRLS) is reduced by at least 10% after the administration compared to a baseline.
6. The method according to claim 5 , wherein the subject's IRLS is reduced by at least 50% after the administration compared to a baseline.
7. The method according to claim 1 , wherein the leucine is DL-leucine.
8. The method according to claim 1 , wherein the acetyl-leucine is acetyl-DL-leucine.
9. The method according to claim 1 , wherein the leucine has an enantiomeric excess of the L-enantiomer or the D-enantiomer.
10. The method according to claim 1 , wherein the acetyl-leucine has an enantiomeric excess of the L-enantiomer or the D-enantiomer.
11. The method according to claim 1 , wherein the method comprises administering the acetyl-leucine to the subject in need thereof at a therapeutically effective amount chosen from about 1 g to about 15 g per day, about 1 g to about 10 g per day, about 1.5 g to about 7 g per day, about 4 g to about 6 g per day, and about 4 g to about 5 g per day.
12. A method of diminishing, inhibiting, or eliminating one or more symptoms of restless legs syndrome (RLS) in a subject in need thereof comprising:
administering a therapeutically effective amount of leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof to the subject.
13. The method according to claim 12 , wherein the one or more symptoms are chosen from lower leg sensations, periodic leg movements of sleep, unpleasant leg sensations, urge to move, restlessness, daytime sleepiness, and sleep disturbances.
14. The method according to claim 12 , wherein the leucine is DL-leucine.
15. The method according to claim 12 , wherein the acetyl-leucine is acetyl-DL-leucine.
16. The method according to claim 12 , wherein the leucine has an enantiomeric excess of the L-enantiomer or the D-enantiomer.
17. The method according to claim 12 , wherein the acetyl-leucine has an enantiomeric excess of the L-enantiomer or the D-enantiomer.
18. The method according to claim 12 , wherein the therapeutically effective amount of the leucine, acetyl-leucine, or pharmaceutically acceptable salt thereof, is chosen from about 1 g to about 15 g per day, about 1 g to about 10 g per day, about 1.5 g to about 7 g per day, about 4 g to about 6 g per day, and about 4 g to about 5 g per day.